From: Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma
Variates | Univariate analysis for PFS | Multivariate analysis | Univariate analysis for OS | Multivariate analysis | ||
---|---|---|---|---|---|---|
P value | P value | HR (95% CI) | P value | P value | HR (95% CI) | |
Age (< 60 vs. ≥ 60) | 0.554 |  |  | 0.026 |  |  |
Gender (female vs. male) | 0.740 | Â | Â | 0.739 | Â | Â |
Tumor location (ICC vs. ECC) | 0.139 | Â | Â | 0.462 | Â | Â |
Largest tumor size (≥ 5 cm vs. < 5 cm) | 0.157 |  |  | 0.009 | 0.030 | 1.635 (1.048–2.552) |
ECOG-PS (1–2 vs. 0) |  < 0.001 | 0.063 | 1.618 (0.974–2.688) |  < 0.001 |  < 0.001 | 3.096 (1.832–5.263) |
Treatment line (≥ 2 vs. 0–1) | 0.344 |  |  | 0.007 | 0.004 | 2.247 (1.289–3.922)] |
Combination agents (Chemotherapy vs. target therapy) | 0.026 |  |  | 0.006 | 0.017 | 0.403 (0.191–0.850) |
PD-L1 (CPS ≥ 1 vs. < 1) | 0.002 |  |  | 0.031 |  |  |
PD-L1 (CPS ≥ 5 vs. < 5) |  < 0.001 | 0.004 | 0.467 (0.278–0.784) | 0.001 | 0.001 | 0.424 (0.259–0.694) |
MSI (MSI-H vs. MSS) |  < 0.001 | 0.002 | 0.198 (0.069–0.563) | 0.001 | 0.013 | 0.265 (0.093–0.754) |
TNM stage (IV vs. I–III) | 0.048 |  |  | 0.103 |  |  |
T stage (T3–T4 vs. T1–T2) | 0.946 |  |  | 0.815 |  |  |
N stage (N1–N2 vs. N0) | 0.435 |  |  | 0.199 |  |  |
M stage (M1 vs. M0) | 0.048 | Â | Â | 0.103 | Â | Â |
TMB (≥ 10 vs. < 10 muts/Mb) | 0.002 |  |  | 0.012 |  |  |
SWI/SNF pathway (Mut vs. WT) | 0.004 | Â | Â | 0.026 | Â | Â |
MMR pathway (Mut vs. WT) | 0.008 | Â | Â | 0.016 | Â | Â |
WNT pathway (Mut vs. WT) | 0.012 | Â | Â | 0.228 | Â | Â |